Fusion Antibodies PLC
LSE:FAB
Operating Margin
Fusion Antibodies PLC
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| UK |
|
Fusion Antibodies PLC
LSE:FAB
|
7.6m GBP |
-92%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
974.7B USD |
15%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
148.6B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
132.1B USD |
22%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
32%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.1B CHF |
18%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31B USD |
24%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
179.2B CNY |
27%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
23.9B USD |
15%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
23.2B USD |
29%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.6B EUR |
14%
|
Fusion Antibodies PLC
Glance View
Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Fusion Antibodies PLC's most recent financial statements, the company has Operating Margin of -92.3%.
You don't have any saved screeners yet